Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated with Kesimpta (ofatumumab) using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry (Kesimpta Pregnancy Registry)

First published: 24/11/2022 Last updated: 08/08/2024





## Administrative details

**EU PAS number** 

EUPAS49803

Study ID

49804

**DARWIN EU® study** 

No

Study countries		
Canada		
Germany		
United States		

#### Study description

The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS. The study is expected to enroll for approximately 7 years and follow the pregnant women and their infant(s) over a maximum of 21 months. The primary objective is to estimate and compare the prevalence of major structural defects in fetuses/infants born to Kesimpta exposed pregnant women with MS versus 1) disease-matched pregnant women not exposed to Kesimpta, and 2) healthy pregnant women. The study will be conducted as two sub-studies, namely the Kesimpta-OTIS sub-study and the Kesimpta-DMSKW sub-study, identical in design, run in parallel aiming to combine (meta-analyze) the results obtained from these two sub-studies. Other outcomes of interest include: a pattern of minor structural defects, spontaneous abortion, stillbirth, elective termination, preterm delivery, preeclampsia/eclampsia, small for gestational age infants, and small for age for postnatal growth at one year of age, developmental performance at approximately one year of age, and serious or opportunistic infections in the first year of life.

#### **Study status**

Ongoing

Research institutions and networks

Institutions

## **Novartis Pharmaceuticals**

First published: 01/02/2024

Last updated: 01/02/2024



Deutschsprachigen Multiple Sklerose und Kinderwunsch Register (DMSKW), Germany

## **Networks**

Organization of Teratology Information Specialists (OTIS) Network

First published: 01/02/2024

**Last updated:** 01/02/2024



## Contact details

## **Study institution contact**

Novartis Clinical Disclosure Officer Trialandresults.registries@novartis.com



Trialandresults.registries@novartis.com

## **Primary lead investigator**

## Novartis Clinical Disclosure Officer

**Primary lead investigator** 

# Study timelines

#### Date when funding contract was signed

Planned: 18/03/2021

Actual: 18/03/2021

#### Study start date

Planned: 31/01/2023

Actual: 05/01/2023

#### Data analysis start date

Planned: 28/02/2033

#### **Date of final study report**

Planned: 28/02/2034

# Sources of funding

• Pharmaceutical company and other private sector

# More details on funding

Novartis Pharma AG

## Study protocol

OMB157G2403 (main) - final protocol V1.0 - for submission\_Redacted.pdf (1.29 MB)

# Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

# Other study registration identification numbers and links

FDA/PMR 3901-2, COMB157G2403

# Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

#### Scope of the study:

Safety study (incl. comparative)

#### Main study objective:

The primary objective is to estimate and compare the prevalence of major structural defects in fetus/infants born to Kesimpta exposed pregnant women with MS versus 1) disease-matched pregnant women not exposed to Kesimpta, and 2) healthy pregnant women.

# Study Design

#### Non-interventional study design

Cohort

# Study drug and medical condition

#### Name of medicine

**KESIMPTA** 

## Study drug International non-proprietary name (INN) or common name

**OFATUMUMAB** 

#### **Anatomical Therapeutic Chemical (ATC) code**

(L04AA52) ofatumumab ofatumumab

#### Medical condition to be studied

Multiple sclerosis

# Population studied

#### Age groups

Preterm newborn infants (0 - 27 days)

Term newborn infants (0 - 27 days)

Infants and toddlers (28 days – 23 months)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

#### Special population of interest

Pregnant women

#### **Estimated number of subjects**

725

# Study design details

#### **Outcomes**

The primary outcome of the study is major structural birth defect.

Secondary outcomes:

- Spontaneous abortion/miscarriage
- Stillbirth
- Elective termination
- Preterm delivery
- Preeclampsia / eclampsia
- Pattern of 3 or more minor structural defects
- Small for gestational age
- Postnatal growth small for age at one year of age
- Developmental performance at approximately one year of age
- Serious or opportunistic infections in the first year

#### Data analysis plan

The primary outcome will be estimated in each cohort as a proportion (95% confidence interval) in pregnancies ending in at least one live born infant. As primary comparison, the crude RR and 95% CI for Kesimpta-exposed cohort vs. disease-Matched cohort will be estimated. Due to the observational nature of the study, the crude RR estimate will be further adjusted for potential confounders using propensity score (PS) methods. The primary analysis will be performed using the PS via inverse probability of treatment weighting. The secondary endpoints spontaneous abortion/miscarriage, stillbirth and premature delivery will be analyzed using survival analysis methods, elective termination, preeclampsia/eclampsia, small for gestational age will be analyzed like the primary outcome. Since multiple births will be included, minor structural defects, ASQ, and serious or opportunistic infections will be analyzed using generalized estimating equations approach.

## Data management

## **ENCePP Seal**

The use of the ENCePP Seal has been discontinued since February 2025.

The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

Data source(s), other

- Deutschsprachigen Multiple Sklerose und Kinderwunsch Register (DMSKW), Germany.
- Organization of Teratology Information Specialists (OTIS), Canada.
- Organization of Teratology Information Specialists (OTIS), United States.

#### **Data sources (types)**

Disease registry

Other

#### Data sources (types), other

Prospective patient-based data collection

# Use of a Common Data Model (CDM)

#### **CDM** mapping

No

# Data quality specifications

#### **Check conformance**

Unknown

#### **Check completeness**

Unknown

#### **Check stability**

Unknown

#### **Check logical consistency**

Unknown

## Data characterisation

## **Data characterisation conducted**

No